A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT04442126. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study of NM21-1480 (Anti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific Antibody) in Adult Patients With Advanced Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a first-in-human, open-label, multi-center, Phase 1/2, dose-escalation study with expansion cohorts to evaluate NM21-1480 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose, define the pharmacokinetics, to explore the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult patients with selected advanced solid tumors.
Study identification
- NCT ID
- NCT04442126
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 52 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 19, 2020 (Actual)
- Primary completion
- Feb 6, 2024 (Actual)
- Completion
- Feb 6, 2024 (Actual)
- Last update posted
- May 23, 2025
2020 – 2024
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCHealth Poudre Valley Hospital | Fort Collins | Colorado | 80524 | — |
| Augusta University Medical Center | Augusta | Georgia | 30912 | — |
| Tulane University Medical Center | New Orleans | Louisiana | 70112 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| St. Joseph Mercy Hospital | Ypsilanti | Michigan | 48197 | — |
| Dartmouth Cancer Center | Lebanon | New Hampshire | 03766 | — |
| NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute) | New York | New York | 10016 | — |
| Montefiore Medical Center | The Bronx | New York | 10461-2374 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| Medical University of South Carolina (MUSC) | Charleston | South Carolina | 29425 | — |
| Sarah Cannon Cancer Center | Nashville | Tennessee | 37203 | — |
| The University Of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04442126, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 23, 2025 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04442126 live on ClinicalTrials.gov.